News
The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of certain patients with diffuse midline glioma.
The FDA has expanded the approved indication of IV Avtozma to include the treatment of CRS in patients 2 years of age and older.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback